September 7, 2017
ASLAN Pharmaceuticals announces initiation of first clinical study in hepatocellular carcinoma for varlitinib
August 31, 2017
ASLAN Pharmaceuticals announces first patient enrolled in a global phase 2/3 study for varlitinib in gastric cancer
August 16, 2017
ASLAN Pharmaceuticals announces new research collaboration with Academia Sinica’s Genomic Research Centre in Taiwan
July 25, 2017
ASLAN Pharmaceuticals partners HOPE FOUNDATION to develop cancer care mobile application
July 6, 2017
Dr Carl Firth appointed to Singapore’s Health and Biomedical Sciences International Advisory Council
June 29, 2017
ASLAN Pharmaceuticals announces first patient enrolled in global TreeTopp study for varlitinib in biliary tract cancer
June 12, 2017
ASLAN Pharmaceuticals announces MTD for varlitinib in combination with chemotherapies commonly used in first line gastric cancer
June 7, 2017
ASLAN Pharmaceuticals announces new positive data identifying ASLAN003 as a novel therapeutic agent in Acute Myeloid Leukaemia
June 2, 2017
ASLAN Pharmaceuticals announces publication of new varlitinib data in metastatic solid tumours at ASCO
June 1, 2017
ASLAN Pharmaceuticals commences first day of trading on Taipei Exchange